

Supplement material

Supplement table S1: STROBE Statement—Checklist of items that should be included in reports of *cohort studies*

| | Item No | Recommendation | Page No |
|------------------------------|--------------------|---|----------------|
| Title and abstract | 1 | (a) Indicate the study's design with a commonly used term in the title or the abstract | 1 |
| | | (b) Provide in the abstract an informative and balanced summary of what was done and what was found | 1 |
| Introduction | | | |
| Background/rationale | 2 | Explain the scientific background and rationale for the investigation being reported | 2 |
| Objectives | 3 | State specific objectives, including any prespecified hypotheses | 2 |
| Methods | | | |
| Study design | 4 | Present key elements of study design early in the paper | 2 |
| Setting | 5 | Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection | 3 |
| Participants | 6 | (a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up (b) For matched studies, give matching criteria and number of exposed and unexposed | 3 2 |
| Variables | 7 | Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable | 3 |
| Data sources/ measurement | 8* | For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group | 2 |
| Bias | 9 | Describe any efforts to address potential sources of bias | 2 |
| Study size | 10 | Explain how the study size was arrived at | 2 |
| Quantitative variables | 11 | Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why | 3 |
| Statistical methods | 12 | (a) Describe all statistical methods, including those used to control for confounding (b) Describe any methods used to examine subgroups and interactions | 3 3 |

| | | | |
|-------------------|-----|--|----------------------|
| | | (c) Explain how missing data were addressed | 3 |
| | | (d) If applicable, explain how loss to follow-up was addressed | 2 |
| | | (e) Describe any sensitivity analyses | 3 |
| Results | | | |
| Participants | 13* | (a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed | 2,4 |
| | | (b) Give reasons for non-participation at each stage | NA |
| | | (c) Consider use of a flow diagram | |
| Descriptive data | 14* | (a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders | 4 |
| | | (b) Indicate number of participants with missing data for each variable of interest | NA |
| | | (c) Summarise follow-up time (eg, average and total amount) | NA |
| Outcome data | 15* | Report numbers of outcome events or summary measures over time | 4 |
| Main results | 16 | (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included | 4, table 2 |
| | | (b) Report category boundaries when continuous variables were categorized | 4 |
| | | (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period | NA |
| Other analyses | 17 | Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses | Page 6; Table 3,4 |
| Discussion | | | |
| Key results | 18 | Summarise key results with reference to study objectives | 8 |

| | | | |
|------------------|----|--|-----|
| Limitations | 19 | Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias | 9 |
| Interpretation | 20 | Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence | 8,9 |
| Generalisability | 21 | Discuss the generalisability (external validity) of the study results | 9 |

Other information

| | | | |
|---------|----|---|---|
| Funding | 22 | Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based | 9 |
|---------|----|---|---|

*Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at <http://www.strobe-statement.org>.

Supplement Table S2. Distribution of study characteristics by occupational branches

| | | | | | | | | | | | | | | |
|----------------------------------|------|------|------|------|--------|------|------|------|------|------|--------|------|--------|------|
| No | 7736 | 99.8 | 7327 | 99.7 | 15,359 | 99.8 | 6440 | 99.7 | 3632 | 99.8 | 12,593 | 99.7 | 13,083 | 99.8 |
| Yes | 19 | 0.2 | 21 | 0.3 | 30 | 0.2 | 17 | 0.3 | 9 | 0.2 | 35 | 0.3 | 29 | 0.2 |
| <i>Other mental disorders</i> | | | | | | | | | | | | | | |
| No | 7635 | 98.5 | 7237 | 98.5 | 15,065 | 97.9 | 6334 | 98.1 | 3554 | 97.6 | 12,259 | 97.1 | 12,807 | 97.7 |
| Yes | 120 | 1.5 | 111 | 1.5 | 324 | 2.1 | 123 | 1.9 | 87 | 2.4 | 369 | 2.9 | 305 | 2.3 |
| <i>Musculoskeletal disorders</i> | | | | | | | | | | | | | | |
| No | 7263 | 93.7 | 6810 | 92.7 | 14,444 | 93.9 | 6093 | 94.4 | 3414 | 93.8 | 11,762 | 93.1 | 12,286 | 93.7 |
| Yes | 492 | 6.3 | 538 | 7.3 | 945 | 6.1 | 364 | 5.6 | 227 | 6.2 | 866 | 6.9 | 826 | 6.3 |
| <i>Other somatic disorders</i> | | | | | | | | | | | | | | |
| No | 4774 | 61.6 | 4239 | 57.7 | 8785 | 57.1 | 3791 | 58.7 | 1824 | 50.1 | 6124 | 48.5 | 7378 | 56.3 |
| Yes | 2981 | 38.4 | 3109 | 42.3 | 6604 | 42.9 | 2666 | 41.3 | 1817 | 49.9 | 6504 | 51.5 | 5734 | 43.7 |

Supplement table S3. Labor market marginalization, sickness absence / disability pension and unemployment days by occupation branches

| | | Manufacturing | Construction | Trade and communication | Financial and business service | Education and research | Health and social care | Other |
|--|-----------------------------------|---------------|---------------|-------------------------|--------------------------------|------------------------|------------------------|---------------|
| Mean days (standard deviation) | Labor market marginalization days | 133 (286) | 122 (267) | 117 (270) | 127 (280) | 117 (262) | 138 (296) | 126 (278) |
| | SA/DP* days | 59 (222) | 59 (206) | 63 (222) | 59 (221) | 76 (226) | 94 (262) | 65 (225) |
| | Unemployment days | 74 (160) | 63 (146) | 54 (138) | 68 (158) | 41 (115) | 44 (123) | 60 (148) |
| Percentage of experiencing the outcome | Any labor market marginalization | 50 | 50 | 46 | 45 | 50 | 54 | 48 |
| | Any SA/DP* days | 27 | 30 | 29 | 25 | 36 | 41 | 29 |
| | Any unemployment days | 35 | 32 | 28 | 31 | 25 | 25 | 31 |
| Median days (interquartile range) among those who experiencing the outcome | Labor market marginalization days | 114 (48, 269) | 127 (55, 286) | 110 (47, 271) | 138 (55, 309) | 102 (43, 215) | 105 (43, 250) | 116 (48, 287) |
| | SA/DP* days | 70 (33, 177) | 69 (31, 168) | 73 (34, 179) | 74 (31, 206) | 82 (32, 178) | 79 (34, 196) | 74 (33, 194) |
| | Unemployment days | 117 (55, 244) | 135 (63, 264) | 115 (53, 243) | 132 (62, 267) | 94 (46, 188) | 100 (43, 213) | 113 (53, 243) |

*SA/DP sickness absence and disability pension

Supplement table S4. Labor market marginalization (LMM), sickness absence/ disability pension (SA/DP) and unemployment (UE) days in individuals with and without attention deficit hyperactivity disorders (ADHD) by occupational branches

| | Manufacturing | | Construction | | Trade and communication | | Financial and business service | | Education and research | | Health and social care | | Other | |
|--|-------------------------------|-----------|-------------------------------|-----------|-------------------------------|-----------|--------------------------------|-----------|-------------------------------|-----------|-------------------------------|-----------|-------------------------------|-----------|
| | Diagnosed by ADHD at baseline | | Diagnosed by ADHD at baseline | | Diagnosed by ADHD at baseline | | Diagnosed by ADHD at baseline | | Diagnosed by ADHD at baseline | | Diagnosed by ADHD at baseline | | Diagnosed by ADHD at baseline | |
| | No | Yes | No | Yes | No | Yes | No | Yes | No | Yes | No | Yes | No | Yes |
| Mean (SD days) | | | | | | | | | | | | | | |
| LMM | 94 (194) | 516 (601) | 88 (193) | 460 (532) | 84 (192) | 452 (557) | 89 (197) | 505 (563) | 87 (195) | 416 (528) | 100 (215) | 514 (590) | 93 (207) | 453 (554) |
| SA/DP | 30 (117) | 350 (562) | 35 (131) | 302 (482) | 37 (135) | 324 (535) | 29 (123) | 354 (541) | 52 (159) | 314 (494) | 61 (175) | 423 (575) | 40 (145) | 316 (529) |
| UE | 65 (148) | 167 (229) | 53 (132) | 158 (226) | 47 (128) | 128 (196) | 60 (147) | 151 (225) | 35 (103) | 102 (190) | 39 (116) | 91 (172) | 53 (138) | 137 (212) |
| Percentage of individuals experiencing the outcome | | | | | | | | | | | | | | |
| LMM | 46 | 84 | 46 | 84 | 43 | 82 | 41 | 82 | 46 | 82 | 51 | 85 | 45 | 82 |
| SA/DP | 23 | 63 | 27 | 64 | 26 | 62 | 21 | 61 | 33 | 66 | 38 | 72 | 26 | 61 |
| UE | 32 | 63 | 29 | 64 | 25 | 58 | 28 | 61 | 23 | 53 | 23 | 48 | 28 | 59 |
| Mean days (standard deviation) among those who experiencing the outcome | | | | | | | | | | | | | | |
| LMM | 203 (243) | 617 (608) | 190 (247) | 549 (538) | 196 (253) | 551 (569) | 214 (259) | 618 (564) | 188 (251) | 508 (542) | 195 (268) | 608 (595) | 207 (268) | 555 (566) |
| SA/DP | 127 (214) | 553 (620) | 130 (228) | 469 (532) | 142 (235) | 519 (597) | 139 (238) | 582 (590) | 157 (246) | 478 (542) | 159 (253) | 586 (603) | 153 (250) | 515 (595) |
| UE | 201 (201) | 265 (240) | 184 (189) | 247 (241) | 187 (198) | 222 (214) | 209 (212) | 249 (243) | 157 (166) | 191 (225) | 171 (191) | 189 (207) | 188 (205) | 234 (232) |

SD: standard deviation.

Supplement table S5. Associations between Attention Deficit Hyperactivity Disorder (ADHD) diagnosis and labour market marginalization (LMM). Incidence rate ratios (IRR) of LMM days and Odds Ratios (OR) of probability of >0 LMM days

| Variables | Labour market marginalization days | | Sickness absence/ disability pension days | | Unemployment days | |
|--|------------------------------------|--------------------|---|--------------------|--------------------|--------------------|
| | IRR (95% CI) | IRR (95% CI) | IRR (95% CI) | IRR (95% CI) | IRR (95% CI) | IRR (95% CI) |
| ADHD diagnosis (ref: no) | | | | | | |
| Yes | 1.48 (1.43–1.54) | 1.48 (1.43–1.54) | 1.70 (1.62 – 1.79) | 1.71 (1.62 – 1.79) | 1.13 (1.08 – 1.19) | 1.13 (1.08 – 1.19) |
| Age (ref: 19-24) | | | | | | |
| 25-29 | 1.33 (1.30 – 1.36) | 1.33 (1.30 – 1.37) | 1.23 (1.19 – 1.27) | 1.23 (1.19 – 1.27) | 1.40 (1.36 – 1.45) | 1.41 (1.36 – 1.45) |
| Gender (ref: female) | | | | | | |
| Male | 1.16 (1.13 – 1.19) | 1.13 (1.10 – 1.16) | 0.95 (0.92 – 0.99) | 0.98 (0.94 – 1.01) | 1.23 (1.19 – 1.27) | 1.20 (1.16 – 1.24) |
| Years of education (ref: 0-9 years) | | | | | | |
| 10-12 years | 0.78 (0.75 – 0.81) | 0.78 (0.76 – 0.81) | 0.84 (0.81 – 0.88) | 0.84 (0.80 – 0.88) | 0.81 (0.77 – 0.84) | 0.81 (0.78 – 0.84) |
| >12 years | 0.65 (0.62 – 0.68) | 0.65 (0.63 – 0.68) | 0.71 (0.67 – 0.75) | 0.70 (0.66 – 0.74) | 0.72 (0.69 – 0.76) | 0.73 (0.69 – 0.77) |
| Country of origin (ref: Sweden) | | | | | | |
| Nordic countries | 0.98 (0.85 – 1.14) | 0.98 (0.84 – 1.14) | 1.04 (0.86 – 1.26) | 1.04 (0.86 – 1.26) | 1.08 (0.89 – 1.33) | 1.08 (0.88 – 1.32) |
| European Union | 1.34 (1.24 – 1.46) | 1.34 (1.23 – 1.45) | 1.15 (1.03 – 1.29) | 1.15 (1.03 – 1.29) | 1.37 (1.23 – 1.52) | 1.36 (1.23 – 1.51) |
| Outside EU | 1.33 (1.28 – 1.38) | 1.33 (1.28 – 1.38) | 1.04 (0.98 – 1.10) | 1.04 (0.98 – 1.09) | 1.38 (1.31 – 1.44) | 1.38 (1.31 – 1.44) |
| Family status (ref: single without children) | | | | | | |
| Single with children | 1.13 (1.06 – 1.21) | 1.14 (1.06 – 1.22) | 1.12 (1.03 – 1.22) | 1.12 (1.03 – 1.21) | 1.07 (0.97 – 1.17) | 1.08 (0.98 – 1.18) |
| Married or cohabitant without children | 1.09 (1.02 – 1.16) | 1.09 (1.02 – 1.16) | 1.08 (0.99 – 1.17) | 1.08 (0.99 – 1.17) | 1.06 (0.97 – 1.16) | 1.07 (0.97 – 1.16) |
| Married or cohabitant with children | 0.94 (0.91 – 0.97) | 0.94 (0.91 – 0.98) | 0.93 (0.89 – 0.97) | 0.93 (0.89 – 0.97) | 1.00 (0.95 – 1.05) | 1.00 (0.96 – 1.05) |
| Region (ref: large city) | | | | | | |
| Medium-sized cities | 1.04 (1.01 – 1.07) | 1.04 (1.01 – 1.07) | 1.04 (1.00 – 1.07) | 1.04 (1.00 – 1.07) | 1.01 (0.97 – 1.04) | 1.00 (0.97 – 1.04) |
| Rural areas | 1.04 (1.01 – 1.07) | 1.04 (1.01 – 1.07) | 1.04 (1.00 – 1.08) | 1.04 (1.00 – 1.08) | 0.98 (0.95 – 1.02) | 0.98 (0.94 – 1.02) |
| Income quantile (ref: first) | | | | | | |
| Second quantile | 1.00 (0.97 – 1.03) | 1.00 (0.97 – 1.03) | 0.96 (0.92 – 1.00) | 0.96 (0.92 – 1.00) | 1.04 (1.00 – 1.08) | 1.04 (1.00 – 1.08) |
| Third quantile | 0.86 (0.83 – 0.89) | 0.86 (0.83 – 0.89) | 0.84 (0.81 – 0.88) | 0.85 (0.81 – 0.88) | 0.99 (0.95 – 1.03) | 0.98 (0.94 – 1.02) |
| Fourth quantile | 0.70 (0.67 – 0.72) | 0.69 (0.67 – 0.72) | 0.71 (0.68 – 0.75) | 0.72 (0.68 – 0.76) | 0.90 (0.85 – 0.94) | 0.88 (0.84 – 0.93) |

| Blue/White collar worker (ref: blue) | | | | | | |
|--------------------------------------|---------------------------|---------------------------|---------------------------|---------------------------|---------------------------|---------------------------|
| White collar | 0.96 (0.93 – 0.99) | 0.95 (0.91 – 0.98) | 1.02 (0.97 – 1.07) | 1.01 (0.97 – 1.06) | 0.96 (0.91 – 1.01) | 0.95 (0.90 – 1.00) |
| Type of work (ref: employee) | | | | | | |
| Self-employed | 0.97 (0.89 – 1.04) | 0.95 (0.88 – 1.03) | 1.05 (0.95 – 1.16) | 1.05 (0.95 – 1.16) | 1.02 (0.92 – 1.13) | 1.00 (0.90 – 1.11) |
| SA before baseline (ref: no) | | | | | | |
| Yes | 1.44 (1.40 – 1.49) | 1.44 (1.40 – 1.49) | 1.54 (1.48 – 1.60) | 1.55 (1.49 – 1.61) | 1.01 (0.96 – 1.06) | 1.01 (0.96 – 1.06) |
| Common mental disorders (ref no) | | | | | | |
| Depression/bipolar disorders | 1.50 (1.43 – 1.57) | 1.49 (1.42 – 1.57) | 1.57 (1.48 – 1.66) | 1.57 (1.48 – 1.66) | 1.00 (0.94 – 1.07) | 1.00 (0.94 – 1.07) |
| Anxiety/stress-related disorders | 1.39 (1.33 – 1.45) | 1.39 (1.33 – 1.46) | 1.47 (1.39 – 1.54) | 1.47 (1.39 – 1.55) | 0.99 (0.94 – 1.05) | 0.99 (0.94 – 1.05) |
| Autism-spectrum disorders | 1.46 (1.32 – 1.62) | 1.45 (1.31 – 1.61) | 1.66 (1.47 – 1.88) | 1.67 (1.48 – 1.88) | 1.05 (0.92 – 1.19) | 1.05 (0.92 – 1.19) |
| Substance abuse | 1.19 (1.12 – 1.26) | 1.19 (1.12 – 1.26) | 1.22 (1.14 – 1.31) | 1.22 (1.14 – 1.31) | 1.10 (1.03 – 1.18) | 1.10 (1.03 – 1.18) |
| Behavioral/emotional disorders | 1.06 (0.93 – 1.22) | 1.06 (0.93 – 1.22) | 1.08 (0.92 – 1.27) | 1.07 (0.91 – 1.26) | 1.02 (0.87 – 1.21) | 1.02 (0.86 – 1.21) |
| Schizophrenia/psychoses | 1.79 (1.52 – 2.10) | 1.80 (1.53 – 2.11) | 2.16 (1.81 – 2.59) | 2.17 (1.81 – 2.60) | 1.03 (0.84 – 1.26) | 1.03 (0.84 – 1.26) |
| Other mental disorders | 1.37 (1.29 – 1.45) | 1.37 (1.29 – 1.45) | 1.41 (1.32 – 1.52) | 1.41 (1.32 – 1.52) | 0.95 (0.88 – 1.03) | 0.95 (0.87 – 1.02) |
| Somatic disorders (ref: no) | | | | | | |
| Musculoskeletal disorders | 1.13 (1.09 – 1.17) | 1.13 (1.09 – 1.18) | 1.21 (1.16 – 1.27) | 1.21 (1.16 – 1.27) | 0.98 (0.92 – 1.03) | 0.98 (0.93 – 1.03) |
| Other somatic disorders | 1.02 (1.00 – 1.05) | 1.03 (1.00 – 1.05) | 1.09 (1.06 – 1.13) | 1.09 (1.06 – 1.13) | 1.01 (0.98 – 1.04) | 1.01 (0.98 – 1.04) |
| Occupational branch | | | | | | |
| Construction | <i>Not included</i> | <i>Reference</i> | <i>Not included</i> | <i>Reference</i> | <i>Not included</i> | <i>Reference</i> |
| Manufacturing | <i>Not included</i> | 1.05 (1.00 – 1.10) | <i>Not included</i> | 0.92 (0.86 – 0.98) | <i>Not included</i> | 1.10 (1.04 – 1.17) |
| Trade and communication | <i>Not included</i> | 0.96 (0.92 – 1.00) | <i>Not included</i> | 0.98 (0.92 – 1.04) | <i>Not included</i> | 1.00 (0.95 – 1.05) |
| Financial and business services | <i>Not included</i> | 1.08 (1.03 – 1.14) | <i>Not included</i> | 0.97 (0.90 – 1.04) | <i>Not included</i> | 1.13 (1.06 – 1.20) |
| Education and research | <i>Not included</i> | 0.93 (0.87 – 0.99) | <i>Not included</i> | 1.02 (0.94 – 1.10) | <i>Not included</i> | 0.91 (0.84 – 0.99) |
| Health and social care | <i>Not included</i> | 0.94 (0.90 – 0.99) | <i>Not included</i> | 1.03 (0.97 – 1.10) | <i>Not included</i> | 0.94 (0.88 – 0.99) |
| Other | <i>Not included</i> | 1.03 (0.98 – 1.07) | <i>Not included</i> | 1.01 (0.95 – 1.08) | <i>Not included</i> | 1.06 (1.00 – 1.12) |
| | <i>OR (95% CI)</i> |
| ADHD diagnosis (ref: no) | | | | | | |
| Yes | 2.36 (2.17-2.56) | 2.36 (2.17-2.57) | 1.94 (1.80-2.10) | 1.95 (1.81-2.11) | 2.21 (2.06-2.38) | 2.21 (2.06-2.38) |

| | | | | | | |
|--|------------------|------------------|------------------|------------------|------------------|------------------|
| Age (ref: 19-24) | | | | | | |
| 25-29 | 1.10 (1.05-1.14) | 1.10 (1.06-1.15) | 1.15 (1.10-1.20) | 1.15 (1.09-1.20) | 1.03 (0.98-1.07) | 1.05 (1.00-1.09) |
| Gender (ref: female) | | | | | | |
| Male | 0.77 (0.74-0.80) | 0.71 (0.68-0.74) | 0.46 (0.44-0.48) | 0.47 (0.45-0.49) | 1.36 (1.31-1.42) | 1.16 (1.11-1.21) |
| Years of education (ref: 0-9 years) | | | | | | |
| 10-12 years | 0.66 (0.62-0.7) | 0.66 (0.62-0.7) | 0.76 (0.72-0.81) | 0.76 (0.71-0.8) | 0.65 (0.62-0.69) | 0.66 (0.62-0.69) |
| >12 years | 0.46 (0.43-0.49) | 0.47 (0.43-0.5) | 0.62 (0.57-0.67) | 0.61 (0.57-0.66) | 0.42 (0.39-0.45) | 0.43 (0.40-0.46) |
| Country of origin (ref: Sweden) | | | | | | |
| Nordic countries | 0.92 (0.73-1.15) | 0.92 (0.74-1.16) | 0.95 (0.74-1.21) | 0.96 (0.75-1.22) | 0.89 (0.69-1.15) | 0.90 (0.70-1.15) |
| European Union | 1.23 (1.09-1.39) | 1.21 (1.07-1.36) | 1.06 (0.92-1.22) | 1.05 (0.92-1.21) | 1.32 (1.16-1.51) | 1.29 (1.13-1.47) |
| Outside EU | 1.65 (1.55-1.75) | 1.69 (1.59-1.79) | 1.05 (0.98-1.12) | 1.05 (0.98-1.12) | 2.01 (1.89-2.14) | 2.1 (1.97-2.23) |
| Family status (ref: single without children) | | | | | | |
| Single with children | 1.46 (1.27-1.68) | 1.45 (1.26-1.67) | 1.50 (1.32-1.71) | 1.46 (1.28-1.66) | 1.14 (1.01-1.3) | 1.18 (1.04-1.34) |
| Married/cohabitant without children | 1.25 (1.13-1.39) | 1.26 (1.14-1.4) | 1.28 (1.15-1.42) | 1.27 (1.14-1.41) | 1.10 (0.98-1.23) | 1.12 (1-1.25) |
| Married /cohabitant with children | 1.04 (0.98-1.09) | 1.02 (0.97-1.08) | 1.39 (1.31-1.47) | 1.36 (1.28-1.44) | 0.78 (0.73-0.82) | 0.78 (0.74-0.83) |
| Region (ref large cities) | | | | | | |
| Medium-sized cities | 1.31 (1.26-1.36) | 1.29 (1.24-1.35) | 1.09 (1.04-1.14) | 1.07 (1.02-1.12) | 1.45 (1.39-1.51) | 1.45 (1.39-1.52) |
| Rural areas | 1.53 (1.47-1.6) | 1.49 (1.43-1.56) | 1.12 (1.07-1.18) | 1.09 (1.04-1.15) | 1.73 (1.65-1.82) | 1.71 (1.63-1.79) |
| Income quantile (ref: first) | | | | | | |
| Second quantile | 0.96 (0.92-1.01) | 0.96 (0.91-1.01) | 1.11 (1.05-1.17) | 1.11 (1.05-1.17) | 0.88 (0.83-0.92) | 0.87 (0.82-0.91) |
| Third quantile | 0.8 (0.76-0.84) | 0.79 (0.75-0.83) | 1.29 (1.22-1.36) | 1.29 (1.22-1.36) | 0.56 (0.53-0.59) | 0.54 (0.51-0.57) |
| Fourth quantile | 0.55 (0.52-0.58) | 0.51 (0.48-0.54) | 1.16 (1.09-1.24) | 1.16 (1.09-1.24) | 0.3 (0.28-0.32) | 0.27 (0.26-0.29) |
| Blue/White collar worker (ref: blue collar) | | | | | | |
| White collar | 0.80 (0.76-0.84) | 0.8 (0.76-0.84) | 0.83 (0.78-0.88) | 0.85 (0.81-0.91) | 0.77 (0.73-0.82) | 0.74 (0.7-0.79) |
| Type of work (ref: employed) | | | | | | |
| Self-employed | 0.46 (0.41-0.51) | 0.44 (0.39-0.49) | 0.83 (0.73-0.93) | 0.84 (0.74-0.95) | 0.35 (0.31-0.4) | 0.32 (0.28-0.36) |
| SA before baseline (ref: no) | | | | | | |
| Yes | 8.67 (7.85-9.57) | 8.67 (7.85-9.57) | 3.74 (3.5-3.99) | 3.74 (3.5-4) | 1.37 (1.28-1.47) | 1.36 (1.27-1.45) |

| | | | | | | |
|-----------------------------------|---------------------|------------------|---------------------|------------------|---------------------|------------------|
| Common mental disorders (ref: no) | | | | | | |
| Depression/bipolar disorders | 1.76 (1.55-2.00) | 1.77 (1.56-2.02) | 1.98 (1.78-2.21) | 1.98 (1.78-2.21) | 1.24 (1.12-1.37) | 1.26 (1.14-1.39) |
| Anxiety/stress-related disorders | 1.54 (1.38-1.73) | 1.54 (1.38-1.73) | 1.79 (1.63-1.98) | 1.80 (1.63-1.98) | 1.17 (1.06-1.28) | 1.17 (1.07-1.29) |
| Autism-spectrum disorders | 1.49 (1.11-2.02) | 1.51 (1.12-2.04) | 1.58 (1.24-2.02) | 1.62 (1.27-2.07) | 1.15 (0.93-1.41) | 1.14 (0.92-1.4) |
| Substance abuse | 1.63 (1.40-1.90) | 1.62 (1.38-1.89) | 1.31 (1.15-1.49) | 1.30 (1.14-1.48) | 1.35 (1.2-1.51) | 1.34 (1.19-1.5) |
| Behavioral/emotional disorders | 0.94 (0.66-1.34) | 0.94 (0.66-1.34) | 1.18 (0.87-1.59) | 1.19 (0.88-1.61) | 0.96 (0.73-1.25) | 0.96 (0.73-1.26) |
| Schizophrenia/psychoses | 3.17 (1.67-6.03) | 3.18 (1.67-6.06) | 3.42 (2.16-5.42) | 3.33 (2.1-5.27) | 1.19 (0.83-1.7) | 1.21 (0.85-1.74) |
| Other mental disorders | 1.22 (1.03-1.45) | 1.22 (1.03-1.44) | 1.29 (1.12-1.49) | 1.29 (1.12-1.49) | 1.01 (0.89-1.14) | 1.02 (0.9-1.15) |
| Somatic disorders (ref: no) | | | | | | |
| Musculoskeletal disorders | 1.68 (1.56-1.81) | 1.69 (1.57-1.82) | 2.04 (1.9-2.19) | 2.03 (1.89-2.19) | 1.08 (1.01-1.16) | 1.09 (1.01-1.17) |
| Other somatic disorders | 1.54 (1.49-1.6) | 1.54 (1.48-1.59) | 1.84 (1.77-1.92) | 1.83 (1.76-1.9) | 1.14 (1.1-1.19) | 1.14 (1.1-1.19) |
| Occupational branch | | | | | | |
| Construction | <i>Not included</i> | <i>Reference</i> | <i>Not included</i> | <i>Reference</i> | <i>Not included</i> | <i>Reference</i> |
| Manufacturing | <i>Not included</i> | 0.92 (0.85-0.98) | <i>Not included</i> | 0.78 (0.72-0.85) | <i>Not included</i> | 1.05 (0.98-1.13) |
| Trade and communication | <i>Not included</i> | 0.64 (0.60-0.69) | <i>Not included</i> | 0.73 (0.68-0.79) | <i>Not included</i> | 0.65 (0.61-0.7) |
| Financial and business services | <i>Not included</i> | 0.77 (0.71-0.83) | <i>Not included</i> | 0.66 (0.61-0.73) | <i>Not included</i> | 0.94 (0.86-1.02) |
| Education and research | <i>Not included</i> | 0.75 (0.68-0.82) | <i>Not included</i> | 0.87 (0.79-0.97) | <i>Not included</i> | 0.68 (0.62-0.76) |
| Health and social care | <i>Not included</i> | 0.7 (0.66-0.76) | <i>Not included</i> | 0.98 (0.91-1.06) | <i>Not included</i> | 0.53 (0.49-0.58) |
| Other | <i>Not included</i> | 0.77 (0.72-0.83) | <i>Not included</i> | 0.78 (0.72-0.84) | <i>Not included</i> | 0.83 (0.77-0.89) |

CI: confidence interval. Zero inflated binomial regression analysis was used to estimate the odds of not being risk at the outcome and the count of the outcomes during the follow-up. The reciprocal values of the odds ratios and 95% confidence interval is presented in the table.

Supplement table S6. Associations between Attention Deficit Hyperactivity Disorder (ADHD) diagnosis with and without comorbid mental disorder and labour market marginalization (LMM). Incidence rate ratios (IRR) of LMM days and Odds Ratios (OR) of probability of >0 LMM days

| Predictors | ADHD without mental comorbidities | | ADHD with mental comorbidities | |
|--|-----------------------------------|--------------------|--------------------------------|--------------------|
| | OR (95% CI) | IRR (95% CI) | OR (95% CI) | IRR (95% CI) |
| Exposure | | | | |
| No ADHD | Reference | Reference | Reference | Reference |
| ADHD | 2.28 (2.04 -2.54) | 1.47 (1.38 – 1.56) | 4.52 (4.08-5) | 2.42 (2.32 – 2.52) |
| <i>Age groups</i> | | | | |
| 19-24 | Reference | Reference | Reference | Reference |
| 25-29 | 1.07 (1.0 - 1.15) | 1.35 (1.29 – 1.41) | 1.13 (1.07-1.18) | 1.34 (1.29 – 1.38) |
| <i>Gender</i> | | | | |
| Female | Reference | Reference | Reference | Reference |
| Male | 0.72 (0.68-0.78) | 1.14 (1.09 – 1.20) | 0.7 (0.67 - 0.74) | 1.11 (1.08 – 1.15) |
| <i>Years of education</i> | | | | |
| 0-9 years | Reference | Reference | Reference | Reference |
| 10-12 years | 0.62 (0.56 - 0.68) | 0.74 (0.70 – 0.78) | 0.67 (0.62 - 0.72) | 0.80 (0.77 – 0.83) |
| > 12 years | 0.45 (0.40 - 0.50) | 0.62 (0.57 – 0.67) | 0.47 (0.43 - 0.51) | 0.67 (0.63 – 0.70) |
| <i>Country of origin</i> | | | | |
| Sweden | Reference | Reference | Reference | Reference |
| Nordic countries | 0.85 (0.56-1.29) | 0.90 (0.68 – 1.19) | 0.96 (0.73-1.26) | 1.07 (0.90 – 1.28) |
| EU | 1.25 (1.02-1.55) | 1.27 (1.10 – 1.46) | 1.17 (1.01-1.37) | 1.36 (1.23 – 1.51) |
| Outside EU | 1.56 (1.41-1.73) | 1.32 (1.23 – 1.41) | 1.75 (1.62-1.88) | 1.31 (1.25 – 1.38) |
| <i>Family status</i> | | | | |
| Single without children | Reference | Reference | Reference | Reference |
| Single with children | 1.55 (1.20-2.00) | 1.21 (1.06 – 1.38) | 1.39 (1.18-1.65) | 1.08 (0.99 – 1.17) |
| Married or cohabitant without children | 1.19 (0.99-1.42) | 1.16 (1.03 – 1.31) | 1.29 (1.14-1.45) | 1.02 (0.94 – 1.10) |
| Married or cohabitant with children | 0.97 (0.88-1.07) | 0.93 (0.88 – 0.99) | 1.03 (0.97-1.11) | 0.90 (0.87 – 0.94) |
| <i>Region</i> | | | | |

| | | | | |
|------------------------------------|--------------------|--------------------|--------------------|--------------------|
| Large cities | Reference | Reference | Reference | Reference |
| Medium-sized cities | 1.28 (1.2-1.38) | 1.04 (0.99 – 1.09) | 1.29 (1.23-1.35) | 1.03 (0.99 – 1.06) |
| Rural areas | 1.55 (1.43-1.67) | 1.04 (0.98 – 1.09) | 1.45 (1.37-1.53) | 1.01 (0.98 – 1.05) |
| Income quantile | | | | |
| <i>First</i> quantile | Reference | Reference | Reference | Reference |
| second quantile | 0.93 (0.86-1.01) | 1.07 (1.01 – 1.13) | 0.97 (0.91 - 1.03) | 0.95 (0.91 – 0.98) |
| third quantile | 0.77 (0.70 - 0.84) | 0.87 (0.82 – 0.92) | 0.79 (0.75 - 0.85) | 0.83 (0.79 – 0.86) |
| fourth quantile | 0.50 (0.45 - 0.55) | 0.67 (0.63 – 0.72) | 0.51 (0.48 - 0.55) | 0.67 (0.64 – 0.70) |
| <i>Blue/White collar worker</i> | | | | |
| Blue collar | Reference | Reference | Reference | Reference |
| White collar | 0.81 (0.74 - 0.88) | 0.98 (0.92 – 1.05) | 0.79 (0.75 - 0.85) | 0.93 (0.89 – 0.98) |
| Other | 1.08 (0.98 - 1.18) | 0.97 (0.92 – 1.03) | 1.05 (0.98-1.12) | 1.04 (1.00 – 1.09) |
| <i>Type of work</i> | | | | |
| Employed | Reference | Reference | Reference | Reference |
| Self-employede | 0.43 (0.35 - 0.51) | 0.88 (0.76 – 1.02) | 0.44 (0.39 - 0.50) | 0.98 (0.89 – 1.08) |
| <i>SA before baseline (ref no)</i> | | | | |
| Yes | 8.98 (7.56 -10.68) | 1.56 (1.47 – 1.66) | 9.35 (8.29-10.54) | 1.65 (1.59 – 1.71) |
| <i>Somatic disorders (Ref: no)</i> | | | | |
| Musculoskeletal disorders | 1.72 (1.50-1.96) | 1.08 (1.01 – 1.16) | 1.69 (1.54-1.85) | 1.14 (1.09 – 1.20) |
| Other somatic disorders | 1.54 (1.45-1.63) | 1.05 (1.01 – 1.10) | 1.57 (1.50 - 1.64) | 1.04 (1.01 – 1.07) |
| <i>Branch</i> | | | | |
| Construction | Reference | Reference | Reference | Reference |
| Manufacturing | 0.89 (0.79 - 1.01) | 1.05 (0.97 – 1.14) | 0.93 (0.85-1.02) | 1.05 (0.99 – 1.11) |
| Trade and communication | 0.67 (0.60 - 0.74) | 0.95 (0.88 – 1.02) | 0.64 (0.59 - 0.69) | 0.96 (0.91 – 1.02) |
| Financial and business services | 0.77 (0.67 - 0.87) | 1.14 (1.05 – 1.25) | 0.77 (0.70 - 0.85) | 1.04 (0.98 – 1.11) |
| Education and research | 0.76 (0.65 - 0.89) | 0.92 (0.83 – 1.03) | 0.74 (0.66 - 0.83) | 0.94 (0.87 – 1.02) |
| Health and social care | 0.69 (0.61 - 0.77) | 0.93 (0.86 – 1.01) | 0.72 (0.66 - 0.79) | 0.96 (0.91 – 1.02) |
| Other | 0.76 (0.68 - 0.86) | 1.00 (0.93 – 1.08) | 0.78 (0.72 - 0.85) | 1.04 (0.99 – 1.10) |

CI: confidence interval. Zero inflated binomial regression analysis was used to estimate the odds of not being risk at the outcome and the count of the outcomes during the follow-up. The reciprocal values of the odds ratios and 95% confidence interval is presented in the table.